Project

Mouse Luminal Mammary Tumors (CIP)

We propose to use whole genome sequencing and analysis to characterize the genomes of a series of mouse mammary tumors. Results from the mutational analyses of these murine tumors will be further compared to the large amount of available data from human luminal breast cancers.

Mouse Luminal Mammary Tumors (CIP) Details

Center Initiated Projects (CIPs) are proposed by the McDonnell Genome Institute to help fulfill the mission and strategic vision of the NHGRI and NIH. All CIP data will be released in a timely manner via appropriate databases in accordance with NHGRI and NIH guidelines.

Project Summary: In this proposal, we aim to utilize whole genome sequencing and analysis to characterize the genomes of a series of STAT1 -/- derived tumors and of the three cell lines. We feel this would provide an important corollary to our ongoing work in ER+ human breast cancer sequencing. Results from the mutational analyses of the murine tumors will be further compared to the large amount of available WGS and exome data from human luminal breast cancers. Goal #1: To identify the mutational and signaling events which occur along the time course of tumor development using whole genome sequencing and gene expression profiling analyses. Status of Samples: Whole Genome sequencing of 3 cell lines and 5 sample types (10 samples per type), 53 cases total. 3 cell lines in Quality Coverage check. 1 sample type (10 samples) in house (wild-type retired breeder) in Library Construction. Goal #2: To use our advanced low-input library approaches coupled with laser-capture microdissection of specific cells to compare changes in the stromal compartment and the epithelial compartment using whole genome sequencing and analysis. Status of Samples: 5 sample types with an epithelial and stromal dissection for each. 10 samples total for WGS. Samples not in house at this time. Goal #3: To identify the mutational and signaling events in STAT1-/- mammary tumors that progress from ovarian hormone-dependency to independency. Status of Samples: 10 OH-independent STAT1 -/- progression tumors. Samples not in house at this time. Collaborators: Dr. Robert Schreiber. IRB Status: Not applicable (non-human sequencing).